Literature DB >> 17504928

Methylation of the PTEN promoter defines low-grade gliomas and secondary glioblastoma.

John K Wiencke1, Shichun Zheng, Nanette Jelluma, Tarik Tihan, Scott Vandenberg, Tanja Tamgüney, Rachel Baumber, Ramon Parsons, Kathleen R Lamborn, Mitchel S Berger, Margaret R Wrensch, Daphne Adele Haas-Kogan, David Stokoe.   

Abstract

Glioblastoma multiforme (GBM) can present as either de novo or secondary tumors arising from previously diagnosed low-grade gliomas. Although these tumor types are phenotypically indistinguishable, de novo and secondary GBMs are associated with distinct genetic characteristics. PTEN mutations, which result in activation of the phosphoinositide 3-kinase (PI3K) signal transduction pathway, are frequent in de novo but not in secondary GBMs or their antecedent low-grade tumors. Results we present here show that grade II astrocytomas, oligodendrogliomas, and oligoastrocytomas commonly display methylation of the PTEN promoter, a finding that is absent in nontumor brain specimens and rare in de novo GBMs. Methylation of the PTEN promoter correlates with protein kinase B (PKB/Akt) phosphorylation, reflecting functional activation of the PI3K pathway. Our results also demonstrate frequent methylation of the PTEN promoter in grade III astrocytomas and secondary GBMs, consistent with the hypothesis that these tumors arise from lower grade precursors. PTEN methylation is rare in de novo GBMs and is mutually exclusive with PTEN mutations. We conclude that methylation of the PTEN promoter may represent an alternate mechanism by which PI3K signaling is increased in grade II and III gliomas as well as secondary GBMs, a finding that offers new therapeutic approaches in these patients.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17504928      PMCID: PMC1907411          DOI: 10.1215/15228517-2007-003

Source DB:  PubMed          Journal:  Neuro Oncol        ISSN: 1522-8517            Impact factor:   12.300


  50 in total

1.  Epigenetic silencing of the PTEN gene in melanoma.

Authors:  Alireza Mirmohammadsadegh; Alessandra Marini; Sandeep Nambiar; Mohamed Hassan; Andrea Tannapfel; Thomas Ruzicka; Ulrich R Hengge
Journal:  Cancer Res       Date:  2006-07-01       Impact factor: 12.701

2.  Inactivation of the tumor suppressor PTEN/MMAC1 in advanced human prostate cancer through loss of expression.

Authors:  Y E Whang; X Wu; H Suzuki; R E Reiter; C Tran; R L Vessella; J W Said; W B Isaacs; C L Sawyers
Journal:  Proc Natl Acad Sci U S A       Date:  1998-04-28       Impact factor: 11.205

3.  Analysis of complex relationships between age, p53, epidermal growth factor receptor, and survival in glioblastoma patients.

Authors:  M L Simmons; K R Lamborn; M Takahashi; P Chen; M A Israel; M S Berger; T Godfrey; J Nigro; M Prados; S Chang; F G Barker; K Aldape
Journal:  Cancer Res       Date:  2001-02-01       Impact factor: 12.701

4.  Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study.

Authors:  A T van Oosterom; I Judson; J Verweij; S Stroobants; E Donato di Paola; S Dimitrijevic; M Martens; A Webb; R Sciot; M Van Glabbeke; S Silberman; O S Nielsen
Journal:  Lancet       Date:  2001-10-27       Impact factor: 79.321

5.  Survival rates in patients with primary malignant brain tumors stratified by patient age and tumor histological type: an analysis based on Surveillance, Epidemiology, and End Results (SEER) data, 1973-1991.

Authors:  F G Davis; S Freels; J Grutsch; S Barlas; S Brem
Journal:  J Neurosurg       Date:  1998-01       Impact factor: 5.115

6.  Considerations when analyzing the methylation status of PTEN tumor suppressor gene.

Authors:  Michele A Zysman; William B Chapman; Bharati Bapat
Journal:  Am J Pathol       Date:  2002-03       Impact factor: 4.307

7.  Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia.

Authors:  B J Druker; M Talpaz; D J Resta; B Peng; E Buchdunger; J M Ford; N B Lydon; H Kantarjian; R Capdeville; S Ohno-Jones; C L Sawyers
Journal:  N Engl J Med       Date:  2001-04-05       Impact factor: 91.245

8.  PTEN promoter is methylated in a proportion of invasive breast cancers.

Authors:  Salma Khan; Takashi Kumagai; Jaimini Vora; Namrata Bose; Indu Sehgal; Phillip H Koeffler; Shikha Bose
Journal:  Int J Cancer       Date:  2004-11-10       Impact factor: 7.396

9.  Epigenetic and genetic alternation of PTEN in cervical neoplasm.

Authors:  Tak-Hong Cheung; Keith Wing-Kit Lo; So-Fan Yim; Loucia Kit-Ying Chan; Mei-Sze Heung; Chun-Sing Chan; Albert Yu-Kiu Cheung; Tony Kwok-Hung Chung; Yick-Fu Wong
Journal:  Gynecol Oncol       Date:  2004-06       Impact factor: 5.482

10.  Promoter methylation of the PTEN gene is a common molecular change in breast cancer.

Authors:  Jose M García; Javier Silva; Cristina Peña; Vanesa Garcia; Rufo Rodríguez; Miguel A Cruz; Blanca Cantos; Mariano Provencio; Pilar España; Felix Bonilla
Journal:  Genes Chromosomes Cancer       Date:  2004-10       Impact factor: 5.006

View more
  56 in total

1.  Methylation profiling identifies 2 groups of gliomas according to their tumorigenesis.

Authors:  Julien Laffaire; Sibille Everhard; Ahmed Idbaih; Emmanuelle Crinière; Yannick Marie; Aurelien de Reyniès; Renaud Schiappa; Karima Mokhtari; Khê Hoang-Xuan; Marc Sanson; Jean-Yves Delattre; Joëlle Thillet; François Ducray
Journal:  Neuro Oncol       Date:  2010-10-05       Impact factor: 12.300

2.  PTEN gene is infrequently hypermethylated in human esophageal squamous cell carcinoma.

Authors:  Zhenguo Sun; Na Ji; Mingming Bi; Shuai Wang; Xiangyan Liu; Zhou Wang
Journal:  Tumour Biol       Date:  2015-02-28

3.  PTEN gene expression and mutations in the PIK3CA gene as predictors of clinical benefit to anti-epidermal growth factor receptor antibody therapy in patients with KRAS wild-type metastatic colorectal cancer.

Authors:  Arjun Sood; Danielle McClain; Radhashree Maitra; Atrayee Basu-Mallick; Raviraja Seetharam; Andreas Kaubisch; Lakshmi Rajdev; John M Mariadason; Kathryn Tanaka; Sanjay Goel
Journal:  Clin Colorectal Cancer       Date:  2012-01-28       Impact factor: 4.481

4.  FoxM1B regulates NEDD4-1 expression, leading to cellular transformation and full malignant phenotype in immortalized human astrocytes.

Authors:  Bingbing Dai; Russell O Pieper; Dawei Li; Ping Wei; Mingguang Liu; Shiao Y Woo; Kenneth D Aldape; Raymond Sawaya; Keping Xie; Suyun Huang
Journal:  Cancer Res       Date:  2010-03-23       Impact factor: 12.701

Review 5.  The sodium pump alpha1 subunit as a potential target to combat apoptosis-resistant glioblastomas.

Authors:  Florence Lefranc; Robert Kiss
Journal:  Neoplasia       Date:  2008-03       Impact factor: 5.715

6.  Therapeutic targeting of cancers with loss of PTEN function.

Authors:  Lloye M Dillon; Todd W Miller
Journal:  Curr Drug Targets       Date:  2014-01       Impact factor: 3.465

Review 7.  Update on molecular findings, management and outcome in low-grade gliomas.

Authors:  T David Bourne; David Schiff
Journal:  Nat Rev Neurol       Date:  2010-11-02       Impact factor: 42.937

Review 8.  Molecular epigenetics and genetics in neuro-oncology.

Authors:  Raman P Nagarajan; Joseph F Costello
Journal:  Neurotherapeutics       Date:  2009-07       Impact factor: 7.620

Review 9.  Medical therapy of gliomas.

Authors:  Manmeet S Ahluwalia; Susan M Chang
Journal:  J Neurooncol       Date:  2014-07-02       Impact factor: 4.130

10.  PTEN suppresses SPARC-induced pMAPKAPK2 and inhibits SPARC-induced Ser78 HSP27 phosphorylation in glioma.

Authors:  Ridwan Alam; Chad R Schultz; William A Golembieski; Laila M Poisson; Sandra A Rempel
Journal:  Neuro Oncol       Date:  2013-02-03       Impact factor: 12.300

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.